by Allison Kennedy | Dec 16, 2022 | Citation Alerts
Tempo-iMG™ and Tempo-iOligo™ were cited by scientists in a nature.com study where they built a 3D in vitro organoid model of the blood brain barrier (BBB). They chose to build their BBB model based on a composition of multiple neural and glial cell types. By utilizing...
by Karen O'Hanlon Cohrt | Nov 18, 2022 | Trends
Welcome to our new blog series about the blood brain barrier (BBB)! In Part 1, we will give a brief history on the discovery of the BBB, as well as introduce what we know about its composition and biological functions. The blood brain barrier or BBB is a highly...
by Angela L. Huang | Oct 19, 2022 | News
SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following...
by Allison Kennedy | Oct 10, 2022 | Citation Alerts
Tempo-iMG™, human iPSC-derived microglia, was used in a follow-up study cited in plos.org. This study expanded on a previous discovery showing that healthy microglia were able to silence HIV. Citation Summary In the current study, scientists from Case Western Reserve...
by Allison Kennedy | Oct 9, 2022 | Citation Alerts
Tempo-iMG™, Tempo-iCort™, Tempo-iDopaNer™, and Tempo-iMotorNer™ were utilized in a study cited in plos.org that examined the cross-talking relationship between microglia and neurons. It was critical that the researchers deployed Tempo’s iPSC-derivative cell types to...
